Roche Selects Fifth Biologic Target Under Collaboration Agreement With Halozyme

Halozyme, a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, has announced that Roche has selected a fifth exclusive target under the existing license and collaboration agreement.

Under this agreement, Roche will pay Halozyme $4.25 million, which is net of previously paid maintenance fees, for exclusive, global rights for the application of its hyaluronidase enzyme, rHuPH20, to a fifth biologic target.

In December 2006, Halozyme entered into an agreement with Roche to apply Halozyme’s proprietary Enhanze Technology to Roche’s biological therapeutic compounds.

Under the collaboration, Roche has access to Halozyme’s expertise in developing and applying rHuPH20 to Roche targets. Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and Roche target compounds, resulting from the collaboration.